Beta-glucan Compounds for Targeted B Cell Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for modulating B cell functions are limited in their ability to specifically target and regulate B cell activities, particularly in treating conditions like B cell neoplasms and autoimmune diseases, where precise immune response modulation is required without inducing overt inflammation.
Innovation Solution
Development of β-glucan compounds that bind to B cells, either through covalent or affinity linkages, incorporating active moieties such as immunomodulators, antibodies, or cytotoxic agents, to modulate B cell functions, including the production of immunoglobulins and activation states, thereby offering targeted therapeutic or prophylactic options for conditions like B cell chronic lymphocytic leukemia and autoimmune disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional methods are used to modulate B cell functions, then broad immune activation can be achieved, but specificity and ability to target particular B cell activities are limited
Solution Approach 1:
The invention segments the immune modulation function by using β-glucan compounds that specifically bind to CR2 receptors on B cells, separating this specific B cell targeting from other immune cell populations. This allows selective modulation of B cell functions while leaving other immune responses unaffected, thereby improving specificity without sacrificing overall immune adaptability.
Solution Approach 2:
The β-glucan compound acts as an intermediary molecule that mediates between the therapeutic agent and B cells. By incorporating active moieties (cytotoxic agents, immunomodulators, antibodies) conjugated to the β-glucan, the system delivers specific therapeutic effects to B cells through this intermediary carrier, enabling precise functional modulation.
2Reliability
If soluble β-glucans are used to activate the innate immune system, then anti-tumor activity is achieved, but overt production of pro-inflammatory cytokines occurs
Solution Approach 1:
The invention applies local quality by directing the immune activation effect specifically to B cells through CR2 receptor binding, rather than causing systemic pro-inflammatory cytokine production. The β-glucan compound creates a localized immune response at the B cell level, achieving anti-tumor activity without the harmful widespread inflammation associated with conventional soluble β-glucans.
Solution Approach 2:
Instead of using conventional soluble β-glucans that cause broad pro-inflammatory activation, the invention inverts the approach by using β-glucan compounds that specifically target B cells through CR2 binding. This inverted strategy achieves anti-tumor effects through B cell-specific mechanisms rather than through general pro-inflammatory cytokine production.
3Measurement precision
If targeted B cell modulation is implemented, then treatment specificity for B cell neoplasms and autoimmune diseases is improved, but development complexity increases
Solution Approach 1:
The invention merges multiple functions into a single β-glucan compound structure: the CR2 binding capability, the delivery of active moieties (cytotoxic agents, immunomodulators, antibodies), and the B cell specificity are all integrated into one molecule. This consolidation achieves targeted treatment specificity while managing development complexity by combining rather than multiplying separate therapeutic components.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The β-glucan compounds effectively bind to B cells, allowing for the modulation of their biological functions, enabling targeted activation or inhibition, which can be used to treat infectious diseases, cancers, and autoimmune conditions with reduced systemic side effects by enhancing immune responses or suppressing dysregulated antibody production.
Implementation Method 1
the β-glucan moiety and the active moiety may be coupled through a covalent linkage
Implementation Method 2
the β-glucan moiety and the active moiety may be coupled through an affinity linkage
Implementation Method 3
modulate at least one biological function of the B cells, wherein the biological function of the B cells comprises making an immunoglobulin
Data Source
AI summary
Described herein are beta-glucan compounds, compositions, and methods. Generally, the methods exploit the observation that beta-glucan compounds can bind to B cells. Thus, the methods generally include administering a beta-glucan compound to a subject in an amount effective for the beta-glucan compound to bind to a B cell and modulate at least one biological function of the B cell.